Prestige Consumer Healthcare Inc

PBH

61.130USD

-0.870-1.40%

Close 03/25, 16:00（ET）Quotes delayed by 15 min

Prestige Consumer Healthcare Inc's Score

Industry at a Glance

Industry Ranking

7 / 157

Overall Ranking

45 / 4547

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Prestige Consumer Healthcare Inc Highlights

StrengthsRisks

Prestige Consumer Healthcare Inc. is a consumer healthcare products company. The Company is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.

Fairly Valued

The company’s latest PE is 16.30, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 53.20M shares, decreasing 0.30% quarter-over-quarter.

Held by Barrow Hanley

Star Investor Barrow Hanley holds 593.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.12.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

78.200

Target Price

+28.22%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Prestige Consumer Healthcare Inc is 8.56, ranking 47 out of 157 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 283.44M, representing a year-over-year decrease of 2.37%, while its net profit experienced a year-over-year decrease of 23.49%.

Score

Industry at a Glance

Previous score

8.56

Change

0



Financials

6.02

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

9.08

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.72

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Prestige Consumer Healthcare Inc is 7.24, ranking 86 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 16.30, which is 27.29% below the recent high of 20.74 and 387.04% above the recent low of -46.77.

Score

Industry at a Glance

Previous score

7.24

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 7/157

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Prestige Consumer Healthcare Inc is 8.67, ranking 13 out of 157 in the Pharmaceuticals industry. The average price target is 76.00, with a high of 88.00 and a low of 70.00.

Score

Industry at a Glance

Previous score

8.67

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Prestige Consumer Healthcare Inc is 6.87, ranking 45 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 68.43 and the support level at 57.78, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.05

Change

-0.18

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-24

The current institutional shareholding score of Prestige Consumer Healthcare Inc is 10.00, ranking 1 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 112.42%, representing a quarter-over-quarter increase of 3.74%. The largest institutional shareholder is The Vanguard, holding a total of 5.38M shares, representing 11.36% of shares outstanding, with 0.16% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

6.83M

-2.90%

The Vanguard Group, Inc.

Star Investors

5.48M

-2.49%

Ariel Investments, LLC

Star Investors

3.59M

+63.23%

Dimensional Fund Advisors, L.P.

2.59M

+4.83%

Kayne Anderson Rudnick Investment Management, LLC

2.21M

+26.58%

State Street Investment Management (US)

1.96M

-1.74%

Allspring Global Investments, LLC

1.59M

+4.62%

Geode Capital Management, L.L.C.

1.44M

+1.73%

Nomura Investment Management Business Trust

1.62M

-17.60%

Westwood Management Corp. (Texas)

1.14M

+29.47%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Prestige Consumer Healthcare Inc is 9.19, ranking 15 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.44. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Prestige Consumer Healthcare Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Prestige Consumer Healthcare Inc

PBH

8.22 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

8.83 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mckesson Corp

MCK

8.43 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Jazz Pharmaceuticals PLC

JAZZ

8.35 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ligand Pharmaceuticals Inc

LGND

8.33 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Gilead Sciences Inc

GILD

8.32 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment